MedWatch

Eli Lilly has to wait a while longer for FDA verdict

Partners Eli Lilly and Incyte will have to wait until Q3 to find out whether the US health authorities can approve their drug Oluminant as a treatment for atopic dermatitis.

Photo: MIKE SEGAR/REUTERS / X90033

The US Food and Drug Administration (FDA) has extended the review period for Eli Lilly's application to get approval for the drug Olumiant, which treats atopic dermatitis in adults, according to an Eli Lilly press announcement.

The FDA has granted experts three more months to assess the data sets which Eli Lilly and Incyte have submitted for Olumiant, or barictinib, which is already approved in the US as an arthritis treatment.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs